Geriatric assessment and treatment outcomes in older adults with cancer receiving immune checkpoint inhibitors

Karim Welaya, Kah Poh Loh, Susan Messing, Emily Szuba, Allison Magnuson, Supriya Gupta Mohile, Ronald Maggiore

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objectives: Immune checkpoint inhibitors (ICIs)have revolutionized the treatment of cancer, but outcomes in older adults are not well defined. We evaluated the associations of geriatric assessment (GA)domains with treatment-related outcomes in older adults with solid tumors receiving ICIs. Methods: We performed a single-center, retrospective study of patients age ≥65 years diagnosed with solid tumors who received ICIs and were evaluated with a GA from January 2011 to April 2017. Using Wilcoxon rank sum test, we examined the associations of GA domains and treatment-related outcomes, including the number of ICI cycles received, best response, immune-related adverse events (irAEs), and hospitalizations during ICI treatment. Results: We identified 28 patients (median age at ICI treatment = 78 years, range 66–93); 60% had Eastern Cooperative Oncology Group (ECOG)Performance Status of ≥2; 39% had lung cancer; 89% had stage IV cancer; and 50% received pembrolizumab. Seventy-five percent had at least one GA domain impairment. Patients with any instrumental activities of daily living (IADL)impairment received fewer cycles of ICI (median: 2.0 vs. 7.0 cycles, p = 0.02). In this small sample, neither age nor GA domain measures were associated with best response, irAEs, or hospitalization during ICI treatment. Conclusions: Older adults treated with ICIs had a high prevalence of impairments in GA domains, and IADL impairments were associated with shorter duration of ICI treatment. Future prospective studies are needed to evaluate the role of the GA further in this vulnerable patient population in the immunotherapy era.

Original languageEnglish (US)
JournalJournal of Geriatric Oncology
DOIs
StatePublished - Jan 1 2019
Externally publishedYes

Fingerprint

Geriatric Assessment
Neoplasms
Activities of Daily Living
Nonparametric Statistics
Hospitalization
Vulnerable Populations
Therapeutics
Immunotherapy
Lung Neoplasms
Retrospective Studies
Prospective Studies

Keywords

  • Cancer
  • Geriatric assessment
  • Immune checkpoint inhibitors
  • Immunotherapy
  • Older adults

ASJC Scopus subject areas

  • Oncology
  • Geriatrics and Gerontology

Cite this

Geriatric assessment and treatment outcomes in older adults with cancer receiving immune checkpoint inhibitors. / Welaya, Karim; Loh, Kah Poh; Messing, Susan; Szuba, Emily; Magnuson, Allison; Mohile, Supriya Gupta; Maggiore, Ronald.

In: Journal of Geriatric Oncology, 01.01.2019.

Research output: Contribution to journalArticle

Welaya, Karim ; Loh, Kah Poh ; Messing, Susan ; Szuba, Emily ; Magnuson, Allison ; Mohile, Supriya Gupta ; Maggiore, Ronald. / Geriatric assessment and treatment outcomes in older adults with cancer receiving immune checkpoint inhibitors. In: Journal of Geriatric Oncology. 2019.
@article{a95f6da92f7b4feabf1b6ac21b1cb69b,
title = "Geriatric assessment and treatment outcomes in older adults with cancer receiving immune checkpoint inhibitors",
abstract = "Objectives: Immune checkpoint inhibitors (ICIs)have revolutionized the treatment of cancer, but outcomes in older adults are not well defined. We evaluated the associations of geriatric assessment (GA)domains with treatment-related outcomes in older adults with solid tumors receiving ICIs. Methods: We performed a single-center, retrospective study of patients age ≥65 years diagnosed with solid tumors who received ICIs and were evaluated with a GA from January 2011 to April 2017. Using Wilcoxon rank sum test, we examined the associations of GA domains and treatment-related outcomes, including the number of ICI cycles received, best response, immune-related adverse events (irAEs), and hospitalizations during ICI treatment. Results: We identified 28 patients (median age at ICI treatment = 78 years, range 66–93); 60{\%} had Eastern Cooperative Oncology Group (ECOG)Performance Status of ≥2; 39{\%} had lung cancer; 89{\%} had stage IV cancer; and 50{\%} received pembrolizumab. Seventy-five percent had at least one GA domain impairment. Patients with any instrumental activities of daily living (IADL)impairment received fewer cycles of ICI (median: 2.0 vs. 7.0 cycles, p = 0.02). In this small sample, neither age nor GA domain measures were associated with best response, irAEs, or hospitalization during ICI treatment. Conclusions: Older adults treated with ICIs had a high prevalence of impairments in GA domains, and IADL impairments were associated with shorter duration of ICI treatment. Future prospective studies are needed to evaluate the role of the GA further in this vulnerable patient population in the immunotherapy era.",
keywords = "Cancer, Geriatric assessment, Immune checkpoint inhibitors, Immunotherapy, Older adults",
author = "Karim Welaya and Loh, {Kah Poh} and Susan Messing and Emily Szuba and Allison Magnuson and Mohile, {Supriya Gupta} and Ronald Maggiore",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.jgo.2019.05.021",
language = "English (US)",
journal = "Journal of Geriatric Oncology",
issn = "1879-4068",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Geriatric assessment and treatment outcomes in older adults with cancer receiving immune checkpoint inhibitors

AU - Welaya, Karim

AU - Loh, Kah Poh

AU - Messing, Susan

AU - Szuba, Emily

AU - Magnuson, Allison

AU - Mohile, Supriya Gupta

AU - Maggiore, Ronald

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objectives: Immune checkpoint inhibitors (ICIs)have revolutionized the treatment of cancer, but outcomes in older adults are not well defined. We evaluated the associations of geriatric assessment (GA)domains with treatment-related outcomes in older adults with solid tumors receiving ICIs. Methods: We performed a single-center, retrospective study of patients age ≥65 years diagnosed with solid tumors who received ICIs and were evaluated with a GA from January 2011 to April 2017. Using Wilcoxon rank sum test, we examined the associations of GA domains and treatment-related outcomes, including the number of ICI cycles received, best response, immune-related adverse events (irAEs), and hospitalizations during ICI treatment. Results: We identified 28 patients (median age at ICI treatment = 78 years, range 66–93); 60% had Eastern Cooperative Oncology Group (ECOG)Performance Status of ≥2; 39% had lung cancer; 89% had stage IV cancer; and 50% received pembrolizumab. Seventy-five percent had at least one GA domain impairment. Patients with any instrumental activities of daily living (IADL)impairment received fewer cycles of ICI (median: 2.0 vs. 7.0 cycles, p = 0.02). In this small sample, neither age nor GA domain measures were associated with best response, irAEs, or hospitalization during ICI treatment. Conclusions: Older adults treated with ICIs had a high prevalence of impairments in GA domains, and IADL impairments were associated with shorter duration of ICI treatment. Future prospective studies are needed to evaluate the role of the GA further in this vulnerable patient population in the immunotherapy era.

AB - Objectives: Immune checkpoint inhibitors (ICIs)have revolutionized the treatment of cancer, but outcomes in older adults are not well defined. We evaluated the associations of geriatric assessment (GA)domains with treatment-related outcomes in older adults with solid tumors receiving ICIs. Methods: We performed a single-center, retrospective study of patients age ≥65 years diagnosed with solid tumors who received ICIs and were evaluated with a GA from January 2011 to April 2017. Using Wilcoxon rank sum test, we examined the associations of GA domains and treatment-related outcomes, including the number of ICI cycles received, best response, immune-related adverse events (irAEs), and hospitalizations during ICI treatment. Results: We identified 28 patients (median age at ICI treatment = 78 years, range 66–93); 60% had Eastern Cooperative Oncology Group (ECOG)Performance Status of ≥2; 39% had lung cancer; 89% had stage IV cancer; and 50% received pembrolizumab. Seventy-five percent had at least one GA domain impairment. Patients with any instrumental activities of daily living (IADL)impairment received fewer cycles of ICI (median: 2.0 vs. 7.0 cycles, p = 0.02). In this small sample, neither age nor GA domain measures were associated with best response, irAEs, or hospitalization during ICI treatment. Conclusions: Older adults treated with ICIs had a high prevalence of impairments in GA domains, and IADL impairments were associated with shorter duration of ICI treatment. Future prospective studies are needed to evaluate the role of the GA further in this vulnerable patient population in the immunotherapy era.

KW - Cancer

KW - Geriatric assessment

KW - Immune checkpoint inhibitors

KW - Immunotherapy

KW - Older adults

UR - http://www.scopus.com/inward/record.url?scp=85066434709&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066434709&partnerID=8YFLogxK

U2 - 10.1016/j.jgo.2019.05.021

DO - 10.1016/j.jgo.2019.05.021

M3 - Article

AN - SCOPUS:85066434709

JO - Journal of Geriatric Oncology

JF - Journal of Geriatric Oncology

SN - 1879-4068

ER -